• UPDATE  - Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients

    1 month ago - By San Diego Biotechnology

    SAN DIEGO, Oct. 27, 2021 - Sorrento Therapeutics, Inc. announced today positive preliminary results from two Phase 2 studies designed to identify the hospitalized patient population suffering from COVID-19-induced pneumonia and respiratory depression likely to respond to treatment with oral Abivertinib. Abivertinib is a novel small molecule tyrosine...
    Read more ...

     

  • Histogen to Report Third Quarter 2021 Financial Results on November 10, 2021

    1 month ago - By San Diego Biotechnology

    SAN DIEGO, Oct. 27, 2021 - Histogen Inc. , a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that Histogen's financial results for the third quarter will be released after...
    Read more ...

     

  • Viking Therapeutics to Report Financial Results for Third Quarter 2021 on November 3, 2021

    1 month ago - By San Diego Biotechnology

    SAN DIEGO: SAN DIEGO, Oct. 27, 2021 /PRNewswire/ - Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the third quarter 2021, after the market close on...
    Read more ...